FAQs
COMING SOON
What causes cGVHD?
Chronic GVHD happens when the donor’s immune cells (T lymphocytes) see the recipient’s tissues as foreign after a stem cell transplant and mistakenly attack them. Even with careful donor matching, small immune system differences can trigger this reaction.1
Unlike acute GVHD, which appears in the first 100 days, cGVHD develops after Day 100 and can affect many organs. It occurs because the donor immune system does not fully tolerate the recipient’s body, leading to ongoing inflammation and, over time, tissue changes or scarring.1
This immune response is the underlying cause of cGVHD.1
Can cGVHD be prevented?
Doctors work to reduce the risk of cGVHD, but it cannot be completely prevented. Before and after the stem cell transplant, patients receive immunosuppressive medications to calm the donor T cells that might attack the recipient’s tissues. There is no single standard prevention plan—different transplant centers use different combinations of medicines.2
Common medications used to help prevent (and sometimes treat) GVHD include2:
- Chemotherapy drugs that eliminate certain donor T cells
- Calcineurin inhibitors that block immune activation
- Immunosuppressants that lower overall immune response
- Corticosteroids that reduce inflammation
- Biologic therapies that slow or stop immune-driven inflammation
Even with these medicines, some people still develop cGVHD, but early prevention helps lower the risk and may make symptoms less severe.2
Can cGVHD be reversed or cured?
There is no simple cure for cGVHD right now, but it can often be controlled; in many people, it improves enough over time that medicines can be reduced or even stopped. However, many people need ongoing care to control symptoms and maintain quality of life. The long-term goal of treatment is to calm the donor immune system so it tolerates your body and to prevent ongoing damage to your organs.3
A big challenge in cGVHD is fibrosis, which is the medical word for scarring and hardening of tissues (for example, tight skin, stiff joints, or fasciitis). Once deep scarring is established, it can be difficult to fully reverse. However, early treatment can reduce inflammation before it turns into permanent fibrosis. Some therapies, including newer targeted and immune-modulating treatments, may slow or partially improve fibrosis over time. Additionally, physical therapy, stretching, and exercises can help maintain or even regain flexibility and function, even when some scarring is present.3
In many patients, cGVHD becomes milder over the years, and doctors can slowly taper immunosuppressive drugs. Some people eventually reach a point in which cGVHD is quiet and treatment is no longer needed, even though some scars or stiffness may remain.3
Why do I have so many specialists treating me?
Chronic GVHD can affect many different parts of the body so it usually can’t be managed by just 1 doctor. Instead, you are cared for by a multidisciplinary team—a group of specialists who each focus on a different part of your health.3
Your care team may include3:
- Transplant specialists who manage your GVHD and immune system
- Your primary care provider who looks after your overall health
- Organ-specific specialists (such as lung, skin, eye, or liver doctors)
- Nurses and nurse navigators who coordinate your care and answer day-to-day questions
- Support services such as social workers, physical or occupational therapists, nutritionists, and patient support groups
All these team members work together to prevent complications, manage symptoms, support your daily functioning, and protect your quality of life. It may feel like a lot of doctors, but they are all part of 1 big team focused on you.3
What questions should I ask my doctors?
What is the outlook for cGVHD?
Are there any clinical trials for patients with cGVHD like me?
Is the cGVHD steroid-refractory? If so, how do we proceed?
Can you help me with the symptoms I’m experiencing?
Are there any lifestyle changes I can make to help manage my symptoms?
Are there any medications I should be aware of?
Are there any support groups I can become a part of?
How will my healthcare team communicate with each other and with me?
Who should I call if I notice any new symptoms?
How do I make decisions about my treatment?
Treatment decisions for cGVHD are made together between you and your medical team, working as partners. Because cGVHD affects each person differently, your doctors tailor treatment to your specific situation, taking into account which organs are involved, how severe the disease is, your overall health, and your personal quality-of-life goals.4
Your team will explain the available options, starting with standard treatments such as steroids and, if needed, moving to other medications or clinical trials. As you discuss these choices, you’ll weigh the potential benefits against possible side effects, the risk of relapse, how each treatment fits into your daily life, and practical issues such as cost, travel, and whether a therapy requires taking pills at home or visits to the clinic.4
Your voice is essential in this process. Asking questions, sharing your concerns, and expressing what matters most to you helps guide your team toward a plan that feels safe, manageable, and aligned with your goals.4
References
Justiz Vaillant AA, Modi P, Mohammadi O. Graft-Versus-Host Disease. StatPearls. 2025. http://www.ncbi.nlm.nih.gov/books/NBK538235/. Accessed 12/14/2025.
Blood Cancer United. Graft-versus-host disease (GVHD). https://bloodcancerunited.org/blood-cancer-care/adults/types-blood-cancer-treatment/stem-cell-transplantation/allogeneic/graft-versus-host-disease-gvhd Accessed 12/14/2025.
Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606-615. https://doi.org/10.1182/blood-2014-08-551994
Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. Blood. 2019;133(11):1191-1200. https://doi.org/10.1182/blood-2018-04-785899
